The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.
BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent years including the departure of its CEO Dr. Michelle McMurry-Heath after a short tenure. Pharmaceutical Research and Manufacturers of America mostly overshadows it on 340B matters.
The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
